JP2025509278A - 小細胞肺癌を治療する方法 - Google Patents
小細胞肺癌を治療する方法 Download PDFInfo
- Publication number
- JP2025509278A JP2025509278A JP2024553365A JP2024553365A JP2025509278A JP 2025509278 A JP2025509278 A JP 2025509278A JP 2024553365 A JP2024553365 A JP 2024553365A JP 2024553365 A JP2024553365 A JP 2024553365A JP 2025509278 A JP2025509278 A JP 2025509278A
- Authority
- JP
- Japan
- Prior art keywords
- administered
- treatment
- etoposide
- day
- wee1 inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22160556 | 2022-03-07 | ||
| EP22160556.1 | 2022-03-07 | ||
| PCT/EP2023/055751 WO2023170065A1 (en) | 2022-03-07 | 2023-03-07 | Methods of treating small cell lung cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025509278A true JP2025509278A (ja) | 2025-04-11 |
| JPWO2023170065A5 JPWO2023170065A5 (https=) | 2026-03-16 |
| JP2025509278A5 JP2025509278A5 (https=) | 2026-03-16 |
Family
ID=80682926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024553365A Pending JP2025509278A (ja) | 2022-03-07 | 2023-03-07 | 小細胞肺癌を治療する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20260027117A1 (https=) |
| EP (1) | EP4489756A1 (https=) |
| JP (1) | JP2025509278A (https=) |
| KR (1) | KR20240158972A (https=) |
| CN (1) | CN118843466A (https=) |
| AR (1) | AR128711A1 (https=) |
| AU (1) | AU2023232376A1 (https=) |
| CA (1) | CA3253688A1 (https=) |
| IL (1) | IL315441A (https=) |
| MX (1) | MX2024010900A (https=) |
| TW (1) | TW202337469A (https=) |
| WO (1) | WO2023170065A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025186213A1 (en) * | 2024-03-04 | 2025-09-12 | Debiopharm International S.A. | Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor |
| CN118581045A (zh) * | 2024-07-29 | 2024-09-03 | 云南省肿瘤医院(昆明医科大学第三附属医院) | 一株多突变的人小细胞肺癌淋巴结转移原代细胞系及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2608940T3 (es) | 2007-06-15 | 2017-04-17 | Msd K.K. | Derivado de bicicloanilina |
| CN104271576A (zh) | 2012-02-23 | 2015-01-07 | 艾伯维公司 | 激酶的吡啶并嘧啶酮抑制剂 |
| US10703759B2 (en) | 2016-11-16 | 2020-07-07 | Impact Therapeutics, Inc | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones |
| GB201703881D0 (en) * | 2017-03-10 | 2017-04-26 | Almac Discovery Ltd | Pharmaceutical compounds |
| WO2022155202A1 (en) | 2021-01-13 | 2022-07-21 | Schrödinger, Inc. | Fused heterocycles and uses of same |
| WO2022188802A1 (en) * | 2021-03-10 | 2022-09-15 | Impact Therapeutics (Shanghai) , Inc | Use of wee1 kinase inhibitors in the treatment of cancer |
| AU2022287033B2 (en) | 2021-06-04 | 2025-04-17 | Aprea Therapeutics, Inc. | Pyridopyrimidine derivatives useful as wee1 kinase inhibitors |
| WO2023093840A1 (en) * | 2021-11-26 | 2023-06-01 | Impact Therapeutics (Shanghai) , Inc | Use of wee1 kinase inhibitors in the treatment of cancer |
-
2023
- 2023-03-07 IL IL315441A patent/IL315441A/en unknown
- 2023-03-07 MX MX2024010900A patent/MX2024010900A/es unknown
- 2023-03-07 EP EP23716186.4A patent/EP4489756A1/en active Pending
- 2023-03-07 CA CA3253688A patent/CA3253688A1/en active Pending
- 2023-03-07 AR ARP230100553A patent/AR128711A1/es unknown
- 2023-03-07 AU AU2023232376A patent/AU2023232376A1/en active Pending
- 2023-03-07 CN CN202380026002.5A patent/CN118843466A/zh active Pending
- 2023-03-07 TW TW112108359A patent/TW202337469A/zh unknown
- 2023-03-07 WO PCT/EP2023/055751 patent/WO2023170065A1/en not_active Ceased
- 2023-03-07 KR KR1020247033425A patent/KR20240158972A/ko active Pending
- 2023-03-07 US US18/844,741 patent/US20260027117A1/en active Pending
- 2023-03-07 JP JP2024553365A patent/JP2025509278A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AR128711A1 (es) | 2024-06-05 |
| US20260027117A1 (en) | 2026-01-29 |
| AU2023232376A1 (en) | 2024-10-10 |
| CN118843466A (zh) | 2024-10-25 |
| KR20240158972A (ko) | 2024-11-05 |
| MX2024010900A (es) | 2024-09-17 |
| WO2023170065A1 (en) | 2023-09-14 |
| CA3253688A1 (en) | 2023-09-14 |
| IL315441A (en) | 2024-11-01 |
| TW202337469A (zh) | 2023-10-01 |
| EP4489756A1 (en) | 2025-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240226090A1 (en) | Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan | |
| KR102713072B1 (ko) | 두경부암 치료를 위한 egfr 저해제 | |
| CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| TWI764943B (zh) | 一種抗pd-1抗體和vegfr抑制劑聯合在製備治療癌症的藥物中的用途 | |
| US9532984B2 (en) | Therapeutic combination for cancer treatment | |
| JP6805336B2 (ja) | 薬学的組み合わせ | |
| AU2020297596A1 (en) | Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome | |
| TWI873485B (zh) | 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案 | |
| EP4110326B1 (en) | Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid | |
| EP4322941A1 (en) | Combination comprising ribociclib and amcenestrant | |
| JP2025509278A (ja) | 小細胞肺癌を治療する方法 | |
| TW202329946A (zh) | 用於治療癌症之方法及包含cdk2抑制劑之給藥方案 | |
| KR20240112931A (ko) | 암 치료를 위한 cdk4 억제제 | |
| EP2663318B1 (en) | Pharmaceutical composition for treating cancer | |
| US9980953B2 (en) | Combined composition for preventing or treating cancer comprising a benzophenone thiazole derivatives as a VDA and topoisomerase inhibitor | |
| RU2849370C1 (ru) | Способы и схемы дозирования, содержащие ингибитор cdk2 и ингибитор cdk4, для лечения рака | |
| AU2024343230A1 (en) | Combination of a wee1 inhibitor and a pkmyt1 inhibitor | |
| HK40110657A (zh) | 用於治疗癌症的cdk4抑制剂 | |
| CA2993451C (en) | Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin | |
| HK40116611A (zh) | 用於治疗癌症的包含cdk2抑制剂和cdk4抑制剂的方法和给药方案 | |
| WO2018074409A1 (ja) | 慢性骨髄性白血病を治療又は寛解するための医薬組成物 | |
| WO2017201226A1 (en) | Combination therapies using indazolylbenzamide derivatives for the treatment of cancer | |
| WO2010004337A1 (en) | Combinations comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2- (4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and pemetrexed |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260306 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260306 |